[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopause-hot-flashes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopause-hot-flashes":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,80,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100609735","phase-4-the-effect-of-tirzepatide-on-menopausal-vasomotor-symptoms-and-biological-aging-in-post-menopausal-women-with-obesity-100609735",false,"NCT07218445","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study","Inclusion Criteria\n\n* Postmenopausal women defined as 12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \\> 40 mIU\u002Fml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.\n* Age 46-60 years old.\n* BMI ≥30 kg\u002Fm2 or BMI ≥27 kg\u002Fm2 in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).\n* Presence of bothersome hot flashes (≥ 28 episodes per week and of sufficient severity to prompt patients to seek therapeutic interventions).\n* Hot flashes must be present for \\>30 days prior to study entry.\n* Ability to participate in all portions of the study, including willingness to self-inject drug\n* Provided informed consent to be part of the study.\n* Willingness and capability to follow a hypocaloric diet, consisting of an energy deficit of approximately 500 kcal\u002Fday compared to baseline total energy expenditure, and composed of 30% from fat, 20% from protein, and 50% of carbohydrate. In addition to performing at least 150 min\u002Fweek of physical activity\n\nExclusion Criteria\n\n* Current treatment with menopausal hormone therapy.\n* Any current (past 4 weeks) or planned use of:\n\n  * Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).\n  * Vaginal estrogen.\n  * Androgens.\n  * Progestogens.\n* Current treatment for menopausal symptoms with cognitive behavioral therapy and\u002For hypnosis.\n* Current use of fezolinetant.\n* Menopause as a result of cancer treatments.\n* Impaired renal function (GFR ≤30 ml\u002Fmin\u002F1.73 m²).\n* Thyroid-stimulating hormone ≥7 with low free T4.\n* 10-year ASCVD risk \\> 7.5%.\n* Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignancy, or uncontrolled psychiatric disease.\n* \\>5% change in weight during the 3 months prior to screening and, or eight fluctuation of ≥20 pounds within the past 6 months (self-report).\n* Other obesity medication used within the past 3 months.\n* History of bariatric surgery. Prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty performed \\> 1 year before screening).\n* Past or intended endoscopic and\u002For device-based therapy or removal within last six months.\n* Current or recent (within 3 months) use of medications that may cause weight gain, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers.\n* Current or recent (within 3 months) use of chronic systemic glucocorticoid therapy for over 2 weeks within the past 3 months.\n* Contraindications to GLP-1 receptor agonist therapy as per Tirzepatide (Zepbound ®) label, including a personal or family history of medullary thyroid carcinoma; a history or diagnosis of multiple endocrine neoplasia syndrome type 2; known hypersensitivity to tirzepatide or any of its excipients.\n* Currently enrolled in another clinical study involving an investigational product, or participated in one and received treatment (active or placebo) in the last 30 days.\n* Planned surgical procedures requiring general anesthesia or sedation during the study or within 2 weeks following the last dose of study drug.",true,"FEMALE","46 Years","60 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.",[28,29],"Obesity","Menopause Hot Flashes",[31,32,33,34],"Hot flashes","menopause","Tirzepatide","GLP","RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2026-04-08",{"date":43,"type":22},"2027-09-18",{"name":45,"class":46},"Mayo Clinic","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100639584","phase-3-fezolinetant-and-vascular-health-and-brain-health-100639584","NCT07606664","Fezolinetant and Vascular Health and Brain Health","FAVES-B","Inclusion Criteria:\n\n* Born female\n* Age ≥40 - ≤65 years at the time of the screening visit\n* Body Mass Index (BMI) ≥18 to ≤38 kg\u002Fm2\n* Seeking treatment or relief for moderate to severe VMS associated with menopause\n* Confirmed menopausal as per one of the following criteria at the time of screening: Reporting spontaneous amenorrhea for ≥12 consecutive months; spontaneous amenorrhea for ≥6 and \\\u003C 12 months with follicle-stimulating hormone \\>40 IU\u002FL\n* Negative urine pregnancy test at screening (if \\\u003C12 months of amenorrhea)\n* A minimum average of 7-8 moderate to severe VMS per day, or 50-60 per week prior to randomization as reported in the 7-day hot flash diary\n* Agrees to not participate in another interventional study (pharmaceutical or device) while participating in this current study\n\nExclusion Criteria:\n\n* Pregnancy\u002Flactation (past 6 months)\n* Any treatment for hot flashes with demonstrated efficacy for hot flashes\n* Currently using systemic sex-hormone medications.\n* Currently using cytochrome P450 1A2 (CYP1A2) inhibitors (as listed according to the FDA).\n* Severely elevated blood pressure \\[systolic blood pressure (SBP) \\>180 and\u002For diastolic blood pressure (DBP) \\>110\\]\n* A medical condition or chronic disease (including history of hepatic, renal, cardiovascular, gastrointestinal, pulmonary \\[e.g., moderate asthma\\], endocrine or gynecological disease) or malignancy that could confound interpretation of the study in the opinion of the investigator or study physician\n* Self-reported narcolepsy\n* Previous\u002Fcurrent history of a malignant tumor, except for basal cell carcinoma\n* Participants with known cirrhosis, active liver disease, jaundice, or elevated liver aminotransferases or total bilirubin (ALT, AST, and total bilirubin), should not be enrolled if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory. Participants with ALP \\> 1.5 × ULN and judged clinically significant by the study physician.\n* Severe renal impairment \\[estimated glomerular filtration rate (eGFR) 15 to \\\u003C30 mL\u002Fmin per 1.73 m2\\] or end-stage renal disease (ESRD) (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m2) at screening as per USPI\n* Positive Hepatitis C virus antibody, Hepatitis B surface antigen, and\u002For human immunodeficiency virus antibody screen at screening\n* History within the last 6 months of undiagnosed uterine bleeding\n* Key medical conditions (history of cardiovascular disease, stroke\u002Fcerebrovascular accident, brain injury with loss of consciousness for more than 60 seconds within the last five years, cognitive disorders, brain tumor, dementia, Parkinson's disease, chemotherapy, psychotic disorders)\n* Metal in the body, claustrophobia, or cannot undergo 3T magnetic resonance imaging (MRI); Inability to meet MRI eligibility criteria\n* Lymph node removal on both sides of the body, mastectomy, or dialysis\n* Hysterectomy; levonorgestrel-releasing intrauterine systems initiated before 12 months of spontaneous amenorrhea (Not exclusionary if placed after 12 months of spontaneous amenorrhea), or history of endometrial ablation will be excluded due to inability to stage menopause; Bilateral oophorectomy if completed prior to 12 months of spontaneous amenorrhea\n* Cardiovascular medication use.\n* Prior exposure to fezolinetant or elinzanetant\n* Current participation in another interventional study or participated in an interventional study or received any investigational drug within 3 months\n* Illicit substance use reported in the past week or detected by urine toxicology screen.\n* Subject has any condition, which in the investigator's or study physician's opinion, makes the subject unsuitable for study participation.","40 Years","65 Years",{"count":58,"type":22},220,[60],"PHASE3","The goal of this clinical trial is to learn whether a study drug called fezolinetant impacts cardiovascular and cognitive health in women who have moderate to severe menopausal hot flashes and night sweats.\n\nResearchers will compare fezolinetant to a placebo. A placebo is a pill that looks like the study drug but does not contain any active medicine. This comparison helps researchers understand whether fezolinetant works better than no treatment.\n\nParticipants will:\n\nBe randomly assigned to take either fezolinetant (45 mg) or a placebo once a day for 12 weeks.\n\nVisit the research clinic for regular checkups and tests during the study. Complete tests that measure blood vessel function and cognition.\n\nParticipants and study staff will not know which treatment each participant receives during the study.",[29],[32,64,65,66,67,68],"hot flashes","vascular health","brain health","women's health","cognition","NOT_YET_RECRUITING","2026-05-18",{"date":72,"type":39},"2026-05-26",{"date":74,"type":22},"2026-09-25",{"date":76,"type":22},"2029-12-30",{"name":78,"class":46},"Rebecca Thurston",2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100591029","phase-2-focusing-on-the-menopausal-transition-to-improve-mid-life-womens-health-100591029","NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","Inclusion Criteria:\n\n* aged 45-55\n* In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18\n* No current use of hormone therapy or hormonal contraception\n* Presence of a uterus and at least one ovary in order to track menstrual patterns\n* Have a smartphone and broadband access adequate to accept telehealth appointments\n\nExclusion Criteria:\n\n* Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)\n* Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.\n* Pregnancy or actively trying to get pregnant\n* Inability to adhere to study protocol schedule\n* Untreated alcoholism\n* Un- Diagnosed abnormal uterine bleeding\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\\> 30 kg\u002Fm2.","45 Years","55 Years",{"count":89,"type":22},200,[91,60],"PHASE2","What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",[94,29,95,96],"Menopause","Menopause Related Conditions","Cardiovascular","2026-04-24",{"date":99,"type":39},"2026-04-30",{"date":101,"type":39},"2026-03-01",{"date":103,"type":22},"2030-10-01",{"name":105,"class":46},"University of Colorado, Denver",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100621831","transcranial-electrical-stimulation-for-noninvasive-study-of-menopausalperimenopausal-symptoms-100621831","NCT07375732","Transcranial Electrical Stimulation for Noninvasive Study of Menopausal\u002FPerimenopausal Symptoms","Inclusion Criteria:\n\n* Age between 40 and 60 years\n* Participants falling under stages -2 to +2 in the Stages of Reproductive Aging Workshop (STRAW +10) as defined below:\n* Early menopause transition (Stage -2): Increased variability in menstrual cycle defined as persistent difference of 7 days or more in the length of consecutive cycles. Persistence is defined as recurrence within 10 cycles of the first variable cycle.\n* Late menopause transition (Stage -1): Occurrence of amenorrhea of 60 days or longer.\n* Final Menstrual Period (Stage 0): Have undergone 12 consecutive months without a menstrual period, not due to other medical causes.\n* Early Postmenopause (Stage +1): 5-8 years after final menstrual period.\n* Late Postmenopause (Stage +2): \\>8 years after final menstrual period.\n* Participants having frequent hot flashes (at least once a day).\n\nExclusion Criteria:\n\n* Disorders that may mask or coincide with menopause and peri-menopause, such as: Primary Ovarian Insufficiency, Thyroid disease (Hyper\u002Fhypothyroidism), Hyperprolactinemia, Cushing's syndrome, Endometrial\u002FOvarian Cancer, Polycystic Ovary Syndrome (PCOS), Functional hypothalamic amenorrhea\n* Concurrent drugs:\n* GnRH agonist\u002Fantagonist\n* Tamoxifen\u002Faromatase inhibitors\n* Other conditions: Recent hematoma (\\\u003C48 hours), History of hemorrhagic disorders (any platelet disorder (ITP, TTP, HUS, Glanzmann thrombasthenia), Hemophilia A\u002FB, history of arterial insufficiency, any prior history of malignancy, current pregnancy, a lifetime history of severe, uncontrolled mood disorders (anxiety, depression, bipolar), psychotic disorders, other neural disorders, or heart disease, any condition that makes them unable to perform tasks outlined in experiment, tattoos on sensory testing sites.",{"count":113,"type":22},50,[115],"NA","Participants are being invited to a research study. This research aims to assess the tolerability of transcranial electrical stimulation of the brain, and explore the response of TES on menopausal\u002Fperimenopausal symptoms including hot flashes effects, depression\u002Fanxiety, memory-problems, and muscular problems. This study will assess what types of electrical brain stimulation affect different menopausal related symptoms. This study will help guide the development of electrical stimulation to be used for improving women's health during menopause transition.",[118,29,94,95],"Menopausal Depression",[120,121,122,123,124],"Noninvasive Neuromodulation","Transcranial Electrical Stimulation","Depression","Vasomotor Symptoms","Hot Flashes","2026-01-26",{"date":127,"type":39},"2026-01-29",{"date":129,"type":22},"2026-02",{"date":131,"type":22},"2027-04",{"name":133,"class":46},"Carnegie Mellon University","Menopause-Hot Flashes"]